HAEMONETICS CORP — Director's Dealing 2023

Jan 25, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2023-01-23

Reporting Person: Llorens Josep (EVP, Global Manufacturing)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-23	Common Stock	M	2391	$56.57	Acquired	19625	Direct
2023-01-23	Common Stock	S	2391	$90.00	Disposed	17234	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-23	Non-qualified Stock Option (Right to Buy)	$56.57	M	2391	Disposed	2028-05-18	Common Stock (2391)	Direct

Footnotes

F1: Transaction pursuant to an existing 10b5-1 trading plan.

F2: This number includes unvested restricted stock units previously reported.

F3: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.